Benzinga | Apr 7, 2021 07:37AM EDT

Benchmark Initiates Coverage On Emergent BioSolutions with Buy Rating, Announces Price Target of $150

Benchmark analyst Robert Wasserman initiates coverage on Emergent BioSolutions (NYSE:EBS) with a Buy rating and announces Price Target of $150.